Background and objectives : Although hepatoblastoma (HB) is a rare childhood tumor and constitutes only 0.9% of all pediatric cancers, there was an obvious improvement in risk stratification and prognosis over the last two decades. This study aimed to assess the outcome of HB patients treated in our center and to investigate the impact of different prognostic factors on the survival of these patients. Patients and methods : This was a retrospective study included newly diagnosed patients with HB presented to the Children Cancer Hospital Egypt (CCHE 57357), from July 2007 to June 2015. Patient’s data w ere analyzed for the clinical characteristics and survival outcome of the included patients. Results: One hundred twenty-four children were included during the study period with a median age of 14 months. The tumor was found occupying the entire liver in 25 patients (20%) ; while it was confined to one lobe in 80% of them, portal vein thrombosis was diagnosed in 10 patients, and there were 30 patients (24%) had metastatic disease at presentation. Only five patients (4%) underwent primary surgical excision, and all of them were grossly excised (stage I) ; 77/119 (64.7%) experienced delayed surgery after two to six courses (median, four courses) of C5VD and the overall resection rate was 66%. There were 42 patients (35.3%) failed to do surgical excision either because they still had evident metastatic disease with poor chemotherapy response, or because their tumor remained unresectable after six courses of chemotherapy. The 3-year event-free and overall survivals for the whole studied patients were 45.7% (95% CI, 36.9% - 56.7%), and 66.7% (95% CI, 57.1% - 77.8%) respectively. The 3-year EFS and OS were significantly better in those who underwent surgical excision (68.63% and 80.74% respectively, P-value < 0.001). Also, the survival rates were significantly affected by the presence of metastatic disease at presentation, tumor stage and initial risk grouping of the studied patients. Conclusion: Surgical excision, tumor stage and COG risk grouping are the main prognostic variables affecting patients’ outcome. Efforts to achieve resectability of the tumor either by advanced surgical techniques or by developing effective preoperative treatment, especially for advanced and metastatic disease, are mandatory.
Zimmermann, A. (2005) The Emerging Family of Hepatoblastoma Tumours: From Ontogenesis to Oncogenesis. European Journal of Cancer, 41, 1503-1514. https://doi.org/10.1016/j.ejca.2005.02.035
Ortega, J.A., Douglass, E.C., Feusner, J.H., Reynolds, M., Quinn, J.J., Finegold, M.J., Haas, J.E., King, D.R., Liu-Mares, W., Sensel, M.G. and Krailo, M.D. (2000) Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report from the Children’s Cancer Group and the Pediatric Oncology Group. Journal of Clinical Oncology, 18, 2665-2675. https://doi.org/10.1200/JCO.2000.18.14.2665
Katzenstein, H.M., London, W.B., Douglass, E.C., Reynolds, M., Plaschkes, J., Finegold, M.J. and Bowman, L.C. (2002) Treatment of Unresectable and Metastatic Hepatoblastoma: A Pediatric Oncology Group Phase II Study. Journal of Clinical Oncology, 20, 3438-3444. https://doi.org/10.1200/JCO.2002.07.400
Exelby, P.R., Filler, R.M. and Grosfeld, J.L. (1975) Liver Tumors in Children in the Particular Reference to Hepatoblastoma and Hepatocellular Carcinoma: American Academy of Pediatrics Surgical Section Survey—1974. Journal of Pediatric Surgery, 10, 329-337. https://doi.org/10.1016/0022-3468(75)90095-0
Brown, J., Perilongo, G., Shafford, E., Keeling, J., Pritchard, J., Brock, P., Dicks-Mireaux, C., Phillips, A., Vos, A. and Plaschkes, J. (2000) Pretreatment Prognostic Factors for Children with Hepatoblastoma—Results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL. European Journal of Cancer, 36, 1418-1425. https://doi.org/10.1016/S0959-8049(00)00074-5
Black, C.T., Cangir, A., Choroszy, M. and Andrassy, R.J. (1991) Marked Response to Preoperative High-Dose cis-Platinum in Children with Unresectable Hepatoblastoma. Journal of Pediatric Surgery, 26, 1070-1073. https://doi.org/10.1016/0022-3468(91)90676-K
Douglass, E.C., Green, A.A., Wrenn, E., Champion, J., Shipp, M. and Pratt, C.B. (1985) Effective Cisplatin (DDP) Based Chemotherapy in the Treatment of Hepatoblastoma. Medical and Pediatric Oncology, 13, 187-190. https://doi.org/10.1002/mpo.2950130405
Malogolowkin, M.H., Katzenstein, H.M., Krailo, M. and Meyers, R.L. (2012) Treatment of Hepatoblastoma: The North American Cooperative Group Experience. Frontiers in Bioscience, 4, 1717-1723. https://doi.org/10.2741/e492
Czauderna, P. (2012) Hepatoblastoma throughout SIOPEL Trials—Clinical Lessons Learnt. Frontiers in Bioscience, 4, 470-479. https://doi.org/10.2741/e392
Hishiki, T., Matsunaga, T., Sasaki, F., Yano, M., Ida, K., Horie, H., Kondo, S., Watanabe, K.-I., Oue, T., Tajiri, T., Kamimatsuse, A., Ohnuma, N. and Hiyama, E. (2011) Outcome of Hepatoblastomas Treated Using the Japanese Study Group for Pediatric Liver Tumor (JPLT) Protocol-2: Report from the JPLT. Pediatric Surgery International, 27, 1-8. https://doi.org/10.1007/s00383-010-2708-0
Watanabe, K. (2013) Current Chemotherapeutic Approaches for Hepatoblastoma. International Journal of Clinical Oncology, 18, 955-961. https://doi.org/10.1007/s10147-013-0616-8
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
Pritchard, J., Brown, J., Shafford, E., Perilongo, G., Brock, P., Dicks-Mireaux, C., Keeling, J., Phillips, A., Vos, A. and Plaschkes, J. (2000) Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach—Results of the First Prospective Study of the International Society of Pediatric Oncology. Journal of Clinical Oncology, 18, 3819-3828. https://doi.org/10.1200/JCO.2000.18.22.3819
Malogolowkin, M.H., Katzenstein, H., Krailo, M.D., Chen, Z., Bowman, L., Reynolds, M., Finegold, M., Greffe, B., Rowland, J., Newman, K., Womer, R.B., London, W.B. and Castleberry, R.P. (2006) Intensified Platinum Therapy Is an Ineffective Strategy for Improving Outcome in Pediatric Patients with Advanced Hepatoblastoma. Journal of Clinical Oncology, 24, 2879-2884. https://doi.org/10.1200/JCO.2005.02.6013
Zsiros, J., Brugieres, L., Brock, P., Roebuck, D., Maibach, R., Zimmermann, A., Childs, M., Pariente, D., Laithier, V., Otte, J.-B., Branchereau, S., Aronson, D., Rangaswami, A., Ronghe, M., Casanova, M., Sullivan, M., Morland, B., Czauderna, P., Perilongo, G., International Childhood Liver Tumours Strategy Group (SIOPEL) (2013) Dose-Dense Cisplatin-Based Chemotherapy and Surgery for Children with High-Risk Hepatoblastoma (SIOPEL-4): A Prospective, Single-Arm, Feasibility Study. The Lancet Oncology, 14, 834-842. https://doi.org/10.1016/S1470-2045(13)70272-9
Malogolowkin, M.H., Katzenstein, H.M., Meyers, R.L., Krailo, M.D., Rowland, J.M., Haas, J. and Finegold, M.J. (2011) Complete Surgical Resection Is Curative for Children with Hepatoblastoma with Pure Fetal Histology: A Report from the Children’s Oncology Group. Journal of Clinical Oncology, 29, 3301-3306. https://doi.org/10.1200/JCO.2010.29.3837
Perilongo, G., Shafford, E., Maibach, R., Aronson, D., Brugières, L., Brock, P., Childs, M., Czauderna, P., MacKinlay, G., Otte, J.B., Pritchard, J., Rondelli, R., Scopinaro, M., Staalman, C., Plaschkes, J. and International Society of Paediatric Oncology—SIOPEL 2 (2004) Risk-Adapted Treatment for Childhood Hepatoblastoma Final Report of the Second Study of the International Society of Paediatric Oncology—SIOPEL 2. European Journal of Cancer, 40, 411-421. https://doi.org/10.1016/j.ejca.2003.06.003
Zsíros, J., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Czauderna, P., Roebuck, D., Childs, M., Zimmermann, A., Laithier, V., Otte, J.-B., de Camargo, B., MacKinlay, G., Scopinaro, M., Aronson, D., Plaschkes, J. and Perilongo, G. (2010) Successful Treatment of Childhood High-Risk Hepatoblastoma with Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study. Journal of Clinical Oncology, 28, 2584-2590. https://doi.org/10.1200/JCO.2009.22.4857
Perilongo, G., Maibach, R., Shafford, E., Brugieres, L., Brock, P., Morland, B., de Camargo, B., Zsiros, J., Roebuck, D., Zimmermann, A., Aronson, D., Childs, M., Widing, E., Laithier, V., Plaschkes, J., Pritchard, J., Scopinaro, M., MacKinlay, G. and Czauderna, P. (2009) Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma. The New England Journal of Medicine, 361, 1662-1670. https://doi.org/10.1056/NEJMoa0810613